DIH Holding US, Inc. Q3 2024 Financial Performance Overview
DIH Holding US, Inc. (NASDAQ: DHAI), a leader in developing advanced robotic devices for rehabilitation, recently reported its financial outcomes for the third fiscal quarter ended December 31, 2024. The company’s innovative products aim to cater to individuals requiring intensive rehabilitation due to various physical impairments.
Financial Highlights
In the third quarter of fiscal year 2024, DIH recorded revenues of $15.1 million. This represented a decrease of 21% compared to the previous fiscal quarter of $19 million. The decline in revenue can largely be attributed to reduced device sales, which plummeted by 25.6% year-on-year, while service revenue saw a modest increase of 4% during the same period.
Revenue Breakdown
Further insights reveal that device revenue accounted for $11.7 million, whereas service revenue reached $3.1 million. Notably, revenue from the EMEA regions, which include Europe, the Middle East, and Africa, saw a significant downturn of 29%, while the Americas experienced a more tempered decline of 7%. To address these challenges, DIH has forged partnerships with Nobis Rehabilitation Partners and Zahrawi Group to expand its distribution network.
Management's Perspective
Jason Chen, Chairman and CEO of DIH, stated, "Despite the challenging landscape influenced by ongoing import restrictions and decreased sales in Europe, we have maintained confidence in our strategy for future growth. Our organization remains committed to fulfilling the demand for our products, evidenced by thriving partnerships and a recent public offering that yielded approximately $4.6 million in gross proceeds. We are resolute in our revenue target of between $60 and $67 million for fiscal year 2025."
Operating Income and Expenses Analysis
The gross profit for the third quarter registered at $7.2 million, a notable 30.4% decrease from the prior year, primarily driven by a drop in sales. Selling, general, and administrative expenses surged to $8.2 million, a 50.6% increase from $5.4 million year-on-year. This rise resulted from heightened employee compensation due to expanded headcount and increased professional service costs associated with being publicly listed.
Investments in Future Development
The company also increased its spending on research and development, reaching $1.8 million for the quarter, which is a 7.7% rise compared to the previous year. Continued investment in R&D is essential for maintaining DIH's competitive edge by enhancing its product offerings. As of the end of December, cash and cash equivalents stood at $1.1 million.
Looking Ahead: Outlook for Fiscal Year 2025
For the remainder of fiscal year 2025, DIH remains optimistic, reiterating its revenue guidance of $60 million to $67 million. The company's strategic initiatives, including new partnerships and product innovations, are geared toward navigating current market challenges effectively. DIH is keen on driving revenue and expanding market reach in a fragmented industry ripe for consolidation.
About DIH Holding US, Inc.
DIH is dedicated to advancing health through innovative rehabilitation devices, facilitating improved functional outcomes for individuals with disabilities. The company integrates visual stimulation and interactive technologies to engage patients in intensive rehabilitation training.
Frequently Asked Questions
What are the key highlights from DIH's Q3 2024 report?
The key highlights include $15.1 million in revenue, a 21% decrease year-on-year, and a strategic focus on expanding distribution through partnerships.
How have recent partnerships impacted DIH's distribution?
Collaborations with Nobis Rehabilitation Partners and Zahrawi Group have enhanced DIH's distribution network, aiming to offset regional sales declines, particularly in EMEA.
What are the projections for DIH's revenue in 2025?
DIH anticipates revenue to be between $60 million and $67 million for fiscal year 2025, aiming for a significant recovery from current challenges.
What investments is DIH making in the future?
The company is increasing its investments in research and development to innovate and enhance its product offerings for better patient outcomes.
How can investors contact DIH for more information?
Investors can reach out via email to Greg Chodaczek for any inquiries regarding the company's performance or investment opportunities.
